Key statistics dashboard for Pyxis Oncology, Inc. (PYXS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Stock Data
| Price | $3.34 |
| Market Cap | $212M |
| Enterprise Value | $210.6M |
| Beta | 1.42 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.36 |
| Price / Book | 18.60 |
| P/S | 19.08 |
| EV/EBITDA | -2.52 |
| EV/Sales | 19.08 |
| EV/FCF | -3.10 |
| P/FCF | -3.10 |
| Earnings Yield | -41.51% |
| FCF Yield | -32.10% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 99.76% |
| EBIT Margin | -793.84% |
| EBITDA Margin | -755.93% |
| Operating Margin | -834.44% |
| Net Margin | -803.83% |
| Return on Equity | -215.23% |
| Return on Assets | -161.55% |
| Return on Invested Capital | -314.66% |
| Return on Capital Employed | -335.57% |
Financial Health
| Current Ratio | 1.34 |
| Quick Ratio | 1.34 |
| Cash Ratio | 0.69 |
| Debt / Equity | 1.56 |
| Debt / Assets | 32.47% |
| Net Debt / EBITDA | 0.01 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -7.88 |
Per-Share Data
| Revenue per share | 0.17 |
| Book Value per share | 0.18 |
| Cash per share | 0.52 |
| FCF per share | -1.06 |
| Tangible Book Value per share | 0.18 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.80 |
Related companies: AVIR · CRBU · ENTA · FHTX · HUMA · IMRX · TNYA
Explore sector: Healthcare · Biotechnology
More sections of PYXS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks